Kureha Kagaku Kogyo Kabushiki Kaisha

Fuji Latex Co., Ltd.

Takao Furusho

Chikao Yoshikumi

Shigeaki Muto

Takao Ando

Takayoshi Fujii

Akihiko Kanno

Kenichi Matsunaga

Masahiko Fujii

Kouichi Niimura

Koichi Niimura

Yoshiharu Oguchi

Noriyuki Toyoda

Masaaki Takahashi

Masanori Ikuzawa

Kunitaka Hirose

Isamu Motokawa

Yoko Onishi

Norifumi Sugita

Junji Kakuchi

Minoru Oohara

Naoki Yamamoto

Akira Kobayashi

Minoru Ohara

Yutaka Enomoto

A condom prophylactic against AIDS infection coated with acidic polysaccharides is provided which has an antiviral action and a method of the manufacture thereof. The acidic polysaccharides can be polysaccharides, protein-bound saccharides and glycolipids such as extracts from sea-weeds, extracts from Procaryomycota and Eucaryomycota, carrageenan and so on which have acidic groups such as sulfuric acid group in a portion of polysaccharides. A condom is coated with a solution of said acidic polysaccharides, and optionally with a lubricant. AIDS infection can be prevented without side effect by using a condom of the present invention.

Condom coated with acidic polysaccharides

Disclosed herein are polysaccharides extracted from marine algae and an antiviral drug containing as active ingredient polysaccharides extracted from seaweeds.

Polysaccharides and antiviral drugs containing the same as active

Disclosed herein is a pharmaceutical composition having antirheumatic activity, antithrombotic activity, analgetic activity, antipyretics activity, anti-hyperlipemic activity and anti-inflammatory activity and activities of reducing the level of blood sugar, raising the coronary blood flow, improving the capability of deformation of erythrocytes, reducing the blood pressure, ameliorating proteinuria and proteinemia and regulating production or metabolism of prostaglandins in a mammal in dosage unit form, which comprises a dosage effective to produce said activities of a glycoprotein having a molecular weight of 5000 to 300,000 as determined by ultracentrifugal method and about 18 to 38% by weight of proteins, produced by culturing a basidiomycetous fungal species belonging to the genus Coriolus, extracting the thus proliferated mycelia or fruit bodies with hot water or aqueous alkali solution and removing low molecular weight substances having a molecular weight of less than 5000 from the extract.

Pharmaceutical composition containing a glycoprotein

Disclosed herein are lectins extracted form a plant of the class Dicotyledoneae and an antiretoviral drug comprising as an active ingredient an effective amount of the lectins.

Lectins and antiretroviral drugs containing the lectins as active

Disclosed herein is a pharmaceutical composition having antirheumatic activity, antithrombotic activity, analgetic activity, antipyretic activity, anti-hyperlipemic activity and anti-inflammatory activity and activities of reducing the level of blood sugar, raising the coronary blood flow, improving the capability of deformation of erythrocytes, reducing the blood pressure, ameliorating proteinuria and proteinemia and regulating production or metabolism of prostaglandins in a mammal in dosage unit form, which comprises a dosage effective to produce said activities of a glycoprotein having a molecular weight of 5000 to 300000 as determined by ultracentrifugal method and about 18 to 38% by weight of proteins, produced by culturing a basidiomycetous fungal species belonging to the genus Coriolus, extracting the thus proliferated mycelia or fruit bodies with hot water or aqueous alkali solution and removing low molecular weight substances having a molecular weight of less than 5000 from the extract.

Disclosed herein are the derivatives of substituted cephalosporanic acid represented by the formula (I): ##STR1## wherein R.sup.1 represents a 4-pyridylthiomethyl group, an alpha-aminobenzyl group, a cyanomethyl group or a 1-tetrazolylmethyl group; R.sup.2 represents a hydrogen atom, an acetoxy group or a (5-methyl-1,3,4-thiadiazol-2-yl)thio group; R.sup.3 represents a hydrogen atom, a hydroxyl group, a carbamoyl group, an alkyl group having 1 to 4 carbon atoms or --(CONH).sub.m (CH.sub.2).sub.n --COOH wherein m is 0 or 1, n is 0, 1 or 2 and the carboxyl group may have been converted to a salt or an ester thereof; p is 0, 1 or 2 and X represents carbon atom or nitrogen atom, and antibiotics comprising the derivatives of substituted cephalosporanic acid represented by the formula (I).

N-(substituted)-[7-(2-cyanoacetamido)cephalosporanic]amide derivatives

Disclosed herein are a cephalosporin derivative represented by the formula (I): ##STR1## wherein R.sup.1 represents a halogenoalkyl group, a salt and ester thereof, a process for producing the same, and a pharmaceutical composition and an antibacterial agent comprising the same.

Cephalosporin derivative, process for producing the same and

Disclosed herein are a derivative of a substituted cephalosporanic acid, represented by the formula (I): ##STR1## wherein p is 0, 1 or 2 and R.sup.1 represents a hydrogen atom, a hydroxyl group, a carbamoyl group, an alkyl group having 1 to 4 carbon atoms or --(CONH).sub.m (CH.sub.2).sub.n --COOH wherein m is 0 or 1; n is 0, 1 or 2 and the carboxyl group may have been converted to the salt or the ester thereof, and an antibiotic comprising a derivative of substituted cephalosporanic acid represented by the formula (I).

Derivative of cephalosporanic acid and pharmaceutical composition

Disclosed herein are 7-beta-[2-(2-amino-4-thiazolyl)-2-methoxyiminoacetamido]-3-(2-amino-1,3,4- thiadiazolyl-5-thiomethyl)-3-cepheme-4-carboxylic acid, salts thereof and pivaloyloxymethyl ester thereof, and a pharmaceutical composition containing the same as an active ingredient.

Pivaloyloxymethyl

Disclosed herein is a nucleic acid-containing glycoprotein having molecular weight of 5,000 to 300,000 as determined by ultracentrifugal method; the weight ratio of protein moiety thereof determined by Lowry-Folin's method to saccharide moiety thereof determined by phenol-sulfuric acid method of in the range of 50/50 to 80/20; N-terminal amino acid thereof consisting essentially of tyrosine, leucine or alanine; leucine-phenylalanine-valine as amino acid sequence at C-terminal thereof; the elementary composition consisting essentially of 35.2 to 49.3% of C, 4.8 to 8.0% of H, 4.3 to 12.3% of N, trace to 2.5% of S, trace to 1.2% of P and the balance of O; the isoelectric point of in the range of pH 2.5 to 5.0; and nucleic acid as a component.

Novel nucleic acid-containing glycoprotein

A penicillin derivative having an antibacterial activity similar to a penicillin antibiotic in a living body without affecting the intestinal bacterial colonies, a process for preparing the derivative and a pharmaceutical composition in a dosage unit form containing the derivative as an active ingredient are disclosed.

Penicillin derivative

A cephalosporin derivative having an antibacterial activity similar to a cephalosporin antibiotic in living bodies without affecting the intestinal bacterial colonies, a method for preparing the derivative and a pharmaceutical composition in a dosage unit form containing the derivative as an active ingredient are disclosed.

Cephalosporin derivative

A compound having the general formula (I) is derived from a cephalosporin; ##STR1## wherein R' is a hydrogen atom, an alkyl group having 1 to 4 atoms or an alkali metal and R is --CH.sub.2 COOR', --CH.sub.2 CH.sub.2 SR', ##STR2## or --CH.sub.2 CH.sub.2 COOR' wherein R' is defined above. A pharmaceutical composition containing the compound is excellent in an antibacterial activity, the activity being recovered by the action of an activating enzyme in a living body although the compound per se shows a low activity against the beneficial bacterial colonies in a living body.

Cephalosporin derivative and pharmaceutical composition containing the

A compound having the general formula (I) is derived from a cephalosporin; ##STR1## wherein R' is a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or an alkali metal. A pharmaceutical composition containing the compound is excellent in an antibacterial activity, the activity being recovered by the action of an activating enzyme in a living body although the compound per se shows a low activity against the beneficial bacterial colonies in a living body.

Growing community of inventors

Machida, Japan

Takao Furusho